← Browse by Condition
Medical Condition

philadelphia chromosome positive bcr abl1 positive chronic myelogenous leukemia

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT01746836 Phase 2
Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Enrollment
50 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →